Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides

Patent metadata

Field	Value
Publication number	US-11117917-B2
Application number	US-201916268262-A
Country	US
Kind code	B2
Filing date	Feb 5, 2019
Priority date	May 2, 2012
Publication date	Sep 14, 2021
Grant date	Sep 14, 2021

Abstract

Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

First claim

We claim:

1. A modular composition comprising;
one or more cell penetrating peptides for delivery of an oligonucleotide comprising a peptide sequence selected from the group consisting of SEQ ID NOS: 61, 92, 201, 316-317, 380, 382, 463, 470, and 474, wherein all the amino acids in the peptide sequence are D-amino acids; and
a single stranded or double stranded oligonucleotide;
wherein the one or more cell penetrating peptides are conjugated to the oligonucleotide, optionally via one or more linkers.

2. The modular composition of claim 1 , wherein the cell penetrating peptide is modified by glycosylation, pegylation, methylation, or a combination thereof.

3. The modular composition of claim 1 , comprising 1-8 cell penetrating peptides.

4. The modular composition of claim 1 , comprising 1-4 cell penetrating peptides.

5. The modular composition of claim 1 , wherein the oligonucleotide is single stranded.

6. The modular composition of claim 1 , wherein the oligonucleotide is a double-stranded oligonucleotide comprising a guide strand and a passenger strand.

7. The modular composition of claim 6 , wherein the cell penetrating peptides are conjugated to the guide strand or the passenger strand of the oligonucleotide at different 2′-positions of the ribose rings and/or different terminal 3′ and/or 5′-positions.

8. The modular composition of claim 6 , wherein the cell penetrating peptides are conjugated to both the guide strand and the passenger strand of the oligonucleotide at different 2′-positions of the ribose rings and/or different terminal 3′ and/or 5′-positions.

9. The modular composition of claim 1 , further comprising one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents, conjugated to the oligonucleotide and/or the cell penetrating peptides, optionally via one or more linkers.

10. The modular composition of claim 9 , wherein the targeting ligand is selected from the group consisting of an antibody, a ligand-binding portion of a receptor, a ligand for a receptor, an aptamer, D-galactose, N-acetyl-D-galactose (GalNAc), multivalent N-acetyl-D-galactose, D-mannose, cholesterol, a fatty acid, a lipoprotein, folate, thyrotropin, melanotropin, surfactant protein A, mucin, a carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine, multivalent mannose, multivalent fructose, glycosylated polyaminoacids, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipophilic moiety that enhances plasma protein binding, a steroid, bile acid, vitamin B12, biotin, an RGD peptide, ibuprofen, naproxen, and aspirin.

11. A modular composition comprising:
one or more cell penetrating peptides for delivery of an oligonucleotide comprising a peptide sequence selected from the group consisting of SEQ ID NOs. 61, 92, 134, 137, 200-201, 316-317, 363, 380, 382, 463, 470, and 474, wherein all the amino acids in the peptide sequence are D-amino acids;
a single stranded or double stranded oligonucleotide;
wherein the one or more cell penetrating peptides are conjugated to the oligonucleotide, optionally via one or more linkers;
one or more tetraGalNAc ligands of Formula (I), (II) or (III):

wherein X is —O—, —S—, —CR 1 R 2 — or —NR 1 —; R 1 and R 2 are each independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl; n is 1, 2, 3, or 4; and the bond with “ ” indicates the point of attachment; and
optionally one or more linkers conjugating the tetraGalNAc ligands to the oligonucleotide and/or the cell penetrating peptides.

12. A modular composition comprising;
one or more cell penetrating peptides for delivery of an oligonucleotide comprising a peptide sequence selected from the group consisting of SEO ID Nos. 489-493, 1074, and 1689-1696, wherein all the amino acids in the peptide sequence are D-amino acids; and
a single stranded or double stranded oligonucleotide;
wherein the one or more cell penetrating peptides are conjugated to the oligonucleotide, optionally via one or more linkers.

13. The modular composition of claim 12 , wherein the cell penetrating peptide further comprising one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents, conjugated to the oligonucleotide and/or the cell penetrating peptide, optionally via one or more linkers.

14. The modular composition of claim 13 , wherein the targeting ligand is selected from the group consisting of an antibody, a ligand-binding portion of a receptor, a ligand for a receptor, an aptamer, D-galactose, N-acetyl-D-galactose (GalNAc), multivalent N-acetyl-D-galactose, D-mannose, cholesterol, a fatty acid, a lipoprotein, folate, thyrotropin, melanotropin, surfactant protein A, mucin, a carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine, multivalent mannose, multivalent fructose, glycosylated polyaminoacids, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipophilic moiety that enhances plasma protein binding, a steroid, bile acid, vitamin B12, biotin, an RGD peptide, ibuprofen, naproxen, and aspirin.

15. The modular composition of claim 12 , wherein the cell penetrating peptide is modified by glycosylation, pegylation, methylation, or a combination thereof.

16. The modular composition of claim 12 , comprising 1-8 cell penetrating peptides.

17. The modular composition of claim 12 , wherein the oligonucleotide is single stranded.

18. The modular composition of claim 12 , wherein the oligonucleotide is a double-stranded oligonucleotide comprising a guide strand and a passenger strand.

19. The modular composition of claim 18 , wherein the cell penetrating peptides are conjugated to the guide strand or the passenger strand of the oligonucleotide at different 2′-positions of the ribose rings and/or different terminal 3′ and/or 5′-positions.

20. The modular composition of claim 18 , wherein the cell penetrating peptides are conjugated to both the guide strand and the passenger strand of the oligonucleotide at different 2′-positions of the ribose rings and/or different terminal 3′ and/or 5′-positions.

Assignees

• Sirna Therapeutics Inc

Inventors

• Tellers David
• Colletti Steven L
• Dudkin Vadim
• Aaronson Jeffrey
• Momose Aaron
• Tucker Thomas Joseph
• Yuan Yu
• Calati Kathleen B
• Tian Lu
• Parmar Rubina G
• Shaw Anthony W
• Wang Weimin
• Storr Rachel Anne
• Busuek Marina
• Kowtoniuk Robert A

Classifications

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61K47/549

  Sugars, nucleosides, nucleotides or nucleic acids · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C12N2310/17

  Immunomodulatory nucleic acids · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title